Torno Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Torno Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,000	Closed	-$1.4M	–	265
2024 Q2	$1.4M	Buy	+5,000	New	+$1.19M	0.07%	81

Other funds holding MDGL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Torno Capital's MDGL Position: Q3 2024 in Review

Torno Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2024, closing a stake of 1,000 shares — an estimated $280K sold.

Torno Capital first reported a position in MDGL in Q2 2024 and held it in 1 quarter. The position peaked at $280K in Q2 2024. 257 funds tracked by Wall St. Rank hold MDGL as of Q3 2024.

Torno Capital reported no remaining Madrigal Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Torno Capital sold 1,000 Madrigal Pharmaceuticals shares in Q3 2024, an estimated $280K.
Torno Capital first reported a position in Madrigal Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Torno Capital's Madrigal Pharmaceuticals position peaked at $280K in Q2 2024.
257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2024.

Based on Torno Capital's 13F filing for Q3 2024, filed 13 Nov 2024.